ES-3000 is under clinical development by Escend Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ES-3000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ES-3000 overview
ES-3000 is under development for the treatment of chronic myeloid leukemia, relapsed and refractory acute myeloid leukemia, idiopathic pulmonary fibrosis, hepatic fibrosis, dermal fibrosis and myelodysplastic syndrome. It is administered orally. The drug candidate is tetrandrine is a plant alkaloid acts targeting Wnt/beta-catenin pathway.
The drug candidate was under development for the treatment of triple negative breast cancer.
Escend Pharmaceuticals overview
Escend Pharmaceuticals is developing orally bioavailable small molecules to improve treatment outcomes for patients with cancer orphan disease indications. The company is headquartered in Menlo Park, California, the US.
For a complete picture of ES-3000’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
